The number of CD197−CD45RA+CD27+ CD8+ T-cells, a subtype of partially differentiated effector CD8+ T-cells was also significantly higher in natalizumab-treated MS-patients (Figure 2B). Here, CD8A is linked to myeloid sarcoma.